Senti Biosciences, Inc. (NASDAQ: STRO) operates as a clinical-stage biotechnology enterprise developing next-generation cell and gene therapies using proprietary gene circuits. Analysts and biotech investors monitor its clinical pipeline progress, cash burn runway, and upcoming therapeutic trial milestones to gauge its long-term potential in precision oncology and genetic medicine.